Company / R&D per Share
Esperion Therapeutics, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.23
FY2025
5-year range
$0.23 / $3.91
FY2021-FY2025
Trend
-6.8%
vs FY2024
Sector context
#189 of 208
Health Care
What the data says
Among 208 Health Care companies, Esperion Therapeutics, Inc. is in the bottom 9% for r&d per share. R&D per Share has declined for 6 consecutive years, from $6.55 in FY2019 to $0.23 in FY2025.
Based on SEC 10-K filings.
0.23 in FY2025 with a 5-year CAGR of -46.7%.
Declined from $0.84 to $0.23 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -49.5%
- 5-Year CAGR
- -46.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 208This company $0.23 Sector average $28.82
▼
-99.2% below sector average
Key checks
Key Insights
- Esperion Therapeutics, Inc.'s r&d per share has declined for 6 consecutive years.
- In FY2025, r&d per share decreased 6.8% year-over-year.
- Ranks #189 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.23 | -6.8% |
| FY2024 | $0.25 | -70.4% |
| FY2023 | $0.84 | -53.4% |
| FY2022 | $1.79 | -54.2% |
| FY2021 | $3.91 | -26.8% |
| FY2020 | $5.34 | -18.4% |
| FY2019 | $6.55 | +2.1% |
| FY2018 | $6.41 | +3.9% |
| FY2017 | $6.17 | +140.3% |
| FY2016 | $2.57 | +89.7% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026